A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus - IRAK4
Study identifier:D7860C00005
ClinicalTrials.gov identifier:NCT07433062
EudraCT identifier:N/A
CTIS identifier:N/A
Recruiting
Official Title
A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics and Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus
Medical condition
Type 2 Diabetes Mellitus
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD6793, AZD6793 Placebo
Sex
All
Estimated Enrollment
28
Study type
Interventional
Age
18 Years - 70 Years
Date
Study Start Date: 14 Jan 2026
Estimated Primary Completion Date: 18 Jun 2026
Estimated Study Completion Date: 18 Jun 2026
Study design
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: -
Primary Purpose: Other
Verification:
Verified 01 Feb 2026 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
Sort by status
- All Statuses
- Recruiting
- Not yet recruiting
- Recruiting complete
- Completed
- Other
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Treatment A AZD6793 and metformin | Drug: AZD6793 Participants will receive oral doses of metformin with an interval of 12 hours between doses. The morning doses of metformin will be administered together with AZD6793 (Treatment A). Other Name: Active |
| Experimental: Treatment B Placebo and metformin | Drug: AZD6793 Placebo Participants will receive oral doses of metformin with an interval of 12 hours between doses. The morning doses of metformin will be administered together with AZD6793 placebo (Treatment B). Other Name: Placebo |
